Bortezomib plus intermediate-dose dexamethasone and thalidomide in elderly untreated patients with multiple myeloma: A Chinese experience

American Journal of Hematology

Volumn 85, Issue 7, 2010, Pages 499-501

  Guo, Hongfeng ^a   Zhou, Xin ^a   Jiang, Yuanqiang ^a   Yang, Guohua ^a   Sun, Chao ^a   Zhuang, Yun ^a   Sun, Hongli ^a   Lu, Mize ^a   Qian, Xifeng ^a   Chen, Feng ^a   Mao, Jingjue ^a   Chen, Heng ^a   Xia, Jun ^a   Shen, Yunfeng ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; THALIDOMIDE; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; PYRAZINE DERIVATIVE;

AGED; ARTICLE; CHINESE; CLINICAL ARTICLE; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INFECTION; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGNOSIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; WEAKNESS; CHINA; CLINICAL TRIAL; DISEASE FREE SURVIVAL; REMISSION; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CHINA; DEXAMETHASONE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MULTIPLE MYELOMA; PYRAZINES; REMISSION INDUCTION; THALIDOMIDE; TREATMENT OUTCOME;

EID: 77954930810     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21734     Document Type: Article

References (23)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics. CA Cancer J Clin 2005;55:10-30.
2. Jawed I, Lee CM, Tward JD, et al. Survival outcomes for multiple myeloma over three decades: A surveillance, epidemiology, and end results (SEER) analysis. J Clin Oncol 2007;25 (Part I):8019.
3. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomibin relapsed, refractory myeloma. N Engl J Med 2003;348:2609-2617.
4. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487-2498.
5. Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: Combination therapy improves time to progression. J Clin Oncol 2007;25:3892-3901.
6. Richardson PG, Mitsiades C, Ghobrial I, et al. Beyond single-agent bortezomib: Combination regimens in relapsed multiple myeloma. Curr Opin Oncol 2006;18:598-608.
7. Richardson PG, Sonneveld P, Schuster MW, et al. Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma. Br J Haematol 2007;137:429-435.
8. Zheng W, Wei G, Ye X, et al. Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma: A Chinese experience. Leuk Res 2009;33:1615-1618.
9. Yuan ZG, Hou J, Zhou F, et al. Bortezomib in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma. Zhonghua Xue Ye Xue Za Zhi 2006;27:653-655.
10. Mateos MV, Hernandez JM, Hernandez MT, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: Results of a multicenter phase I/II study. Blood 2006;108:2165-2172.
11. Durie BGM, Harousseau JL, Miguel JS, et al. International uniform response criteria for MM. Leukemia 2006;20:1467-1473.
12. National Cancer Institute Cancer Therapy Evaluation Program Common Toxicity Criteria version 2.0. Available at: http://ctep.cancer.gov/forms/ ctc2nom-4-30-99-final3.pdf.
13. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487-2498.
14. Jagannath S, Richardson PG, Barlogie B, et al. Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica 2006;91:929-934.
15. Richardson P, Sonneveld P, Schuster M, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: Final time-to-event results from the APEX trial. Blood 2007;110:3557-3560.
16. Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: Randomized controlled trial. Lancet 2006;367:825-831.
17. Palumbo A, Bringhen S, Liberati AM, et al. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: Updated results of a randomized controlled trial. Blood 2008;112:3107-3114.
18. Facon T, Mary JY, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): A randomised trial. Lancet 2007;370:1209-1218.
19. San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359:906-917.
20. Wang M, Giralt S, Delasalle K, et al. Bortezomib in combination with thalidome- dexamethasone for previously untreated multiple myeloma. Hematology 2007;12:235-239.
21. Kropff M, Bisping G, Schuck E, et al. Bortezomib in combination with intermediate- dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. Br J Haematol 2007;138:330-337.
22. Zheng W, Wei G, Ye X, et al. Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma: A Chinese experience. Leuk Res 2009;33:1615-1618.
23. Lonial S, Waller EK, Richardson PG, et al. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood 2005;106:3777-3784.